Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Kardigan, Inc. (KARD)

Kardigan Completes KATALYST-AV Enrollment but Pushes Primary Endpoint to Week 48

Mixed Impact 4 of 5 other

Kardigan said it completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis, with 156 participants enrolled. It amended the protocol to assess the primary endpoint of aortic valve calcium at Week 48 instead, and the press release now puts topline data in the second half of 2027, which means a longer wait for shareholders.

Key points

  • 156 participants enrolled in KATALYST-AV; baseline data from the first 139 were analyzed
  • Primary endpoint of aortic valve calcium moved to Week 48; an internal interim analysis is planned for Week 24
  • Press release gives topline data timing as second half of 2027, while the 8-K item text says second half of 2026
  • Investor webcast at the American Heart Association meeting on November 7, 2026, at 8:00 AM ET

The filing

CompanyKardigan, Inc. (KARD)
Form8-K, current report
Filed with the SECNov 6, 2026, 4:06 PM ET
Accession number0001193125-26-451836

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.